Zhao Shankun, Wang Yaoyao, Wu Weizhou, Yang Suqing, Feng Lili, Tao Fangfang, Ge Weiwei, Shen Maolei, Xu Weifang
Department of Urology, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, China.
Second School of Clinical Medicine, Wenzhou Medical University, Wenzhou, China.
Andrologia. 2021 Jul;53(6):e14060. doi: 10.1111/and.14060. Epub 2021 Mar 30.
Nonalcoholic fatty liver disease (NAFLD), the liver component of metabolic syndrome, is considered to be associated with high risk of prostatic diseases but a systematic review has not been conducted. Under a comprehensive review of the eligible clinical studies, a potential positive association between NAFLD and benign prostatic hyperplasia/prostate cancer (BPH/PCa) has been postulated. Insulin resistance and metabolic aberrations are considered to be the potential mechanism for such association. However, the relationship between NAFLD and other prostatic diseases, that is, prostatic inflammation and lower urinary tract symptoms, seems vague due to limited relevant studies in the literatures. The present review highlights that clinicians should be conscious of the detrimental effect of NAFLD on the development of BPH and PCa.
非酒精性脂肪性肝病(NAFLD)是代谢综合征的肝脏组成部分,被认为与前列腺疾病的高风险相关,但尚未进行系统综述。在对符合条件的临床研究进行全面综述后,推测NAFLD与良性前列腺增生/前列腺癌(BPH/PCa)之间可能存在正相关。胰岛素抵抗和代谢异常被认为是这种关联的潜在机制。然而,由于文献中相关研究有限,NAFLD与其他前列腺疾病,即前列腺炎和下尿路症状之间的关系似乎尚不明确。本综述强调,临床医生应意识到NAFLD对BPH和PCa发生发展的有害影响。